Ask AI
ProCE Banner Activity

Precision Management of NSCLC With Biomarker Testing: An APP Perspective

Clinical Thought

Read this commentary for practical, expert insights on NSCLC biomarker testing, including how NPs and PAs can integrate testing into workflows, interpret reports, and help patients understand treatment-relevant results.

Released: July 13, 2026

Share

Provided by

Provided by Partners for Advancing Clinical Education in partnership with Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer, Inc.

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with cancer, particularly lung, colorectal, and prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the clinical significance and implications of biomarker testing, including the role of germline and somatic mutations and their relevance in cancer care

  • Integrate evidence-based and best practice clinical care pathways to facilitate routine and rapid testing across tumor types

  • Interpret molecular profiling reports and biomarker testing results

  • Identify the role of advanced practice providers (APPs) in providing patient and family/care partner education on biomarker testing and treatment recommendations

  • Apply comprehensive communication and educational strategies to minimize health disparities and ensure biomarker testing use and accessibility in diverse patient populations

Financial Disclosures

Primary Author

Denise Rouse, MS, PA-C: consultant/advisor/speaker: Bristol Myers Squibb, Johnson & Johnson, Puma.